Zahedi P - Search Results

1

Optimizing computed tomography simulation wait times in a busy radiation medicine program.

Roussos J, Zahedi P, Spence T, Swanson LA, Li-Cheung F, Cops F, Darcy P, Chhin V, Moyo E, Warde P, Foxcroft S, Liu FF. Roussos J, et al. Among authors: zahedi p. Pract Radiat Oncol. 2017 Jan-Feb;7(1):e77-e83. doi: 10.1016/j.prro.2016.06.007. Epub 2016 Jun 23. Pract Radiat Oncol. 2017. PMID: 27552810

2

Strategic planning in an academic radiation medicine program.

Hamilton JL, Foxcroft S, Moyo E, Cooke-Lauder J, Spence T, Zahedi P, Bezjak A, Jaffray D, Lam C, Létourneau D, Milosevic M, Tsang R, Wong R, Liu FF. Hamilton JL, et al. Among authors: zahedi p. Curr Oncol. 2017 Dec;24(6):e518-e523. doi: 10.3747/co.24.3725. Epub 2017 Dec 20. Curr Oncol. 2017. PMID: 29270061 Free PMC article.

3

The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer.

Kogo R, How C, Chaudary N, Bruce J, Shi W, Hill RP, Zahedi P, Yip KW, Liu FF. Kogo R, et al. Among authors: zahedi p. Oncotarget. 2015 Jan 20;6(2):1090-100. doi: 10.18632/oncotarget.2836. Oncotarget. 2015. PMID: 25473903 Free PMC article.

4

A porphodimethene chemical inhibitor of uroporphyrinogen decarboxylase.

Yip KW, Zhang Z, Sakemura-Nakatsugawa N, Huang JW, Vu NM, Chiang YK, Lin CL, Kwan JY, Yue S, Jitkova Y, To T, Zahedi P, Pai EF, Schimmer AD, Lovell JF, Sessler JL, Liu FF. Yip KW, et al. Among authors: zahedi p. PLoS One. 2014 Feb 25;9(2):e89889. doi: 10.1371/journal.pone.0089889. eCollection 2014. PLoS One. 2014. PMID: 24587102 Free PMC article.

5

Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells.

Cui L, Tse K, Zahedi P, Harding SM, Zafarana G, Jaffray DA, Bristow RG, Allen C. Cui L, et al. Among authors: zahedi p. Radiat Res. 2014 Nov;182(5):475-88. doi: 10.1667/RR13642.1. Epub 2014 Oct 31. Radiat Res. 2014. PMID: 25361396

6

Neoplastic cell response to tiopronin-coated gold nanoparticles.

Cui L, Zahedi P, Saraceno J, Bristow R, Jaffray D, Allen C. Cui L, et al. Among authors: zahedi p. Nanomedicine. 2013 Feb;9(2):264-73. doi: 10.1016/j.nano.2012.05.016. Epub 2012 Jun 9. Nanomedicine. 2013. PMID: 22687897

7

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

De Souza R, Zahedi P, Badame RM, Allen C, Piquette-Miller M. De Souza R, et al. Among authors: zahedi p. Mol Cancer Ther. 2011 Jul;10(7):1289-99. doi: 10.1158/1535-7163.MCT-11-0058. Epub 2011 May 6. Mol Cancer Ther. 2011. PMID: 21551263

8

Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.

Zahedi P, De Souza R, Huynh L, Piquette-Miller M, Allen C. Zahedi P, et al. Mol Pharm. 2011 Feb 7;8(1):260-9. doi: 10.1021/mp100323z. Epub 2010 Dec 17. Mol Pharm. 2011. PMID: 21166459

9

Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel.

Liu J, Zahedi P, Zeng F, Allen C. Liu J, et al. Among authors: zahedi p. J Pharm Sci. 2008 Aug;97(8):3274-90. doi: 10.1002/jps.21245. J Pharm Sci. 2008. PMID: 18064681

10

Polymeric drug delivery systems for localized cancer chemotherapy.

De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. De Souza R, et al. Among authors: zahedi p. Drug Deliv. 2010 Aug;17(6):365-75. doi: 10.3109/10717541003762854. Drug Deliv. 2010. PMID: 20429844 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page